Furthermore, the combination of venetoclax with the Class I (HDAC1‐3‐targeting) inhibitor chidamide and azacitidine demonstrated promising efficacy and an acceptable safety profile in patients with relapsed/refractory (R/R) AML (Zha et al. 2023). This evidence concerns the gene HDAC1 and acute myeloid leukemia.